<DOC>
	<DOC>NCT02309762</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of single-ascending IV doses of FB825</brief_summary>
	<brief_title>A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>1. The subject is male or female between 18 and 55 years of age, inclusive. 2. All female subjects must have a negative serum pregnancy test at screening and on Day −1. 3. The subject has a body weight ≥50 kg at screening and a body mass index of 18 to 30 kg/m2, inclusive. 4. The subject has a good health condition based upon the results of medical history, physical examination, vital signs, laboratory profile and ECG. 5. The subject has a negative urine drug screen for alcohol, cotinine. 1. Female subjects who are pregnant or lactating. 2. The subject has a past history of heart arrhythmias. 3. The subject has history of clinically significant diseases. 4. The subject has any history of a previous anaphylactic reaction. 5. Use of prescribed medication within 6 months of Day −1.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>